TP53 and acute myeloid leukemia: Although TP53 mutations are relatively rare in patients with de novo AML, these mutations has been identified as an important molecular subgroup, and patients with these mutations have the worst prognosis and shortest overall survival among patients with AML, even when treated with aggressive chemotherapy and allogeneic stem cell transplant for relapsed or therapy-related AML.